The PMDA Perspectives on New Oral Prolyl Hydroxylase Domain Enzyme Inhibitors for Renal Anemia.
| Autor: | Tanaka M; Office of New Drug 1, Pharmaceuticals and Medical Devices Agency, Tokyo, Japan., Ikuma M; Office of New Drug 1, Pharmaceuticals and Medical Devices Agency, Tokyo, Japan., Asakura W; Office of New Drug 1, Pharmaceuticals and Medical Devices Agency, Tokyo, Japan., Fujiwara Y; Chief Executive, Pharmaceuticals and Medical Devices Agency, Tokyo, Japan. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Clinical pharmacology and therapeutics [Clin Pharmacol Ther] 2022 Feb; Vol. 111 (2), pp. 358-361. Date of Electronic Publication: 2021 May 16. |
| DOI: | 10.1002/cpt.2275 |
| Databáze: | MEDLINE |
| Externí odkaz: |
|
Plný text